Feasibility of switching from intravenous to subcutaneous immunoglobulin in CIDP: PATH trial and clinical experience

Authors
Category Primary study
JournalClinical Neurophysiology
Year 2019
This article has no abstract
Epistemonikos ID: 40a6ff4de49bdea5ba216e7b3ee3668332f14dac
First added on: Feb 09, 2025